Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist AntibodyCD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
04 Jun 2023
Clinical ResultASCOPhase 2Immunotherapy
- Marked increases in overall survival observed across soft tissue sarcoma patients -
- Demonstrated improvement of median progression free survival in patients with dedifferentiated liposarcoma (DDLPS) -
- DDLPS expansion cohort enrolling to inform a potential Phase 3 registration trial -
SAN CARLOS, CA, USA I June 03, 2023 I Apexigen, Inc. (Nasdaq: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the presentation of new data from a Phase 2 investigator-sponsored trial in collaboration with Columbia University, evaluating sotigalimab (sotiga), Apexigen’s agonist antibody targeting CD40, in combination with standard-of-care doxorubicin (dox), in patients with advanced soft tissue sarcoma (STS). These data were presented in a poster presentation on June 3, 2023 at the ASCO Annual Meeting being held both virtually and in person in Chicago, IL.
Sotiga combined with dox was safe and well tolerated and indicated increases in overall survival (OS) with a median OS of 35.6 months across all STS patients evaluated, which is markedly higher than the historical OS of 12.8 to 20 months of dox alone across STS subtypes. Moreover, subtype-specific analysis demonstrated improvement in median progression-free survival (mPFS) of 10.95 months in patients with dedifferentiated liposarcoma (DDLPS) which is markedly higher than the historical mPFS of 4 months in patients with DDLPS.
“We are excited to present new data at ASCO from the Phase 2 trial in patients with advanced STS that supports further development of sotiga-based combinations and underscores the significant opportunity to provide patients with meaningful clinical benefit characterized by rapid, deep and durable responses with a favorable safety profile,” said Xiaodong Yang, M.D., Ph.D., Chief Executive Officer of Apexigen. “Notably, we are encouraged by the median overall survival results across sarcoma subtypes and the data demonstrating that the subgroup of patients with DDLPS treated with sotiga in combination with dox achieved a mPFS, more than double that seen historically with dox alone. We look forward to building on these impressive findings with our DDLPS expansion cohort, which will potentially inform a Phase 3 registration study in DDLPS.”
Key Takeaways: The open-label, single-arm, multicenter Phase 2 trial enrolled patients with advanced STS, including DDLPS, leiomyosarcoma (LMS), and undifferentiated pleomorphic sarcoma (UPS) and treated patients with a combination of sotiga and dox. The primary endpoint was objective response rate (ORR), and secondary endpoints were progression-free survival and safety.
More information about the study is available here (NCT03719430).
The abstract (#11565) is accessible on the ASCO Congress portal, and additional details are provided below.
About Apexigen
Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents designed to harness the patient’s immune system to combat and eradicate cancer. Sotigalimab and Apexigen’s other programs were discovered using Apexigen’s proprietary APXiMAB™ discovery platform. This platform has enabled Apexigen and its collaboration partners to discover and develop therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Multiple product candidates have been discovered using the APXiMAB platform, one of which is commercially available and the others are in clinical development, either internally by Apexigen or by its licensees. For more information, please visit www.apexigen.com.
SOURCE: Apexigen
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.